23andMe Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Explore the Complete Value Chain Behind the Preview
This 23andMe Value Chain Analysis gives you a clear view of how the company creates value across support and primary activities. The page already shows a real preview of the actual report content, so you can review the format and substance before buying. Purchase the full version for the complete ready-to-use analysis.
Support Activities
Firm Infrastructure
Firm infrastructure coordinated the 2025-26 restructuring under TTAM Research Institute, helping steady governance after 23andMe's liquidity strain and Chapter 11 sale. It set the legal, compliance, and risk controls for the $305 million asset transfer while protecting privacy across 15 million customer records. This support kept the business aligned with a public-benefit model.
Human Resource Management
Human resource management at 23andMe stayed lean after the late-2024 cut of about 40% of headcount, with hiring centered on bioinformatics, privacy law, and lab operations. In FY2025, the Company Name relied on elite data scientists to keep its genetic database useful for research partnerships, not large internal drug discovery teams. This kept talent costs tight while preserving the technical skill needed for preventative health work.
Technology Development
Technology development is 23andMe's main moat, built on a proprietary genomic database of over 15 million genotyped individuals. In fiscal 2025, the company kept investing in the 23andMe+ digital platform, the DaNA chatbot, and bioinformatic pipelines that turn raw DNA data into health reports. Ongoing work on polygenic risk scores supports personalized, longitudinal insights in the membership dashboard.
Procurement
23andMe's procurement centers on bulk sourcing of Illumina SNP genotyping arrays, saliva kits, and cloud contracts, which keeps the DTC testing flow steady. This matters because 23andMe depends on high-volume, low-unit-cost inputs to protect margins in a business where one kit must cover collection, genotyping, storage, and delivery. Tight supplier control also helps safeguard petabyte-scale customer data and avoid stockouts that can delay testing. In 2025, disciplined buying is a core lever for lowering per-kit cost and keeping service consistent.
23andMe FY2025: Restructuring to Keep the Platform Alive
23andMe's support activities in FY2025 were shaped by restructuring and survival: firm infrastructure managed the $305 million TTAM sale, privacy risk, and Chapter 11 controls across more than 15 million customer records. HR stayed lean after a 40% headcount cut, while technology and procurement kept the genomic platform and genotyping supply chain running.
| FY2025 | Key data |
|---|---|
| Sale value | $305 million |
| Customer records | 15 million+ |
| Headcount cut | About 40% |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Inbound logistics at 23andMe covers home delivery and return of saliva kits through shipping partners and tracking, then fast intake at secure fulfillment centers. The company has served more than 15 million customers, so sample flow is high-volume and time sensitive. In FY2025, quick registration and tracked returns helped protect sample integrity and reduce turnaround delays for DNA processing.
Operations
23andMe's operations use CLIA-certified, CAP-accredited labs and high-throughput genotyping to turn saliva into raw DNA data. By FY2025, the Company had built a database of more than 15 million genotyped customers, and its proprietary algorithms convert that data into ancestry and health reports with reported 99%+ call accuracy.
This lab-to-software step creates the core digital IP behind 23andMe's model. FY2025 revenue was about $219 million, showing how much value still comes from processing each sample into usable genetic insights.
Outbound Logistics
Outbound logistics at 23andMe are almost fully digital, with encrypted results delivered through the web account and mobile app, plus raw data files sent only to consenting users and researchers. In fiscal 2025, 23andMe reported revenue of about $219 million, showing how much of the business depends on fast, secure data delivery rather than physical shipping. Premium report alerts and instant access make the last mile of the value chain global, low-cost, and immediate.
Marketing and Sales
23andMe's marketing and sales have shifted from one-time DNA kit pushes to recurring revenue from 23andMe+, which the company says serves over 500,000 active subscribers. That means sales now focus on keeping users engaged, then cross-selling preventative health tools instead of chasing a single kit sale. Direct-to-consumer digital channels and social media also help cut acquisition costs and lift lifetime value.
Service
Service keeps 23andMe relevant after the kit sale by giving 15 million users access to genetic counselors, updated ancestry matches, and real-time health alerts. The 23andMe+ portal turns a one-time purchase into an ongoing preventative health relationship, which can raise repeat use and premium subscriptions. Proactive ancestry relative alerts and fresh predisposition updates also support retention by giving customers a reason to stay engaged.
23andMe Shifts to Recurring Revenue With 500K+ Subscribers
23andMe's primary activities center on digital sales, subscription growth, and post-purchase service. In FY2025, revenue was about $219 million, while the Company said 23andMe+ served more than 500,000 active subscribers, showing a shift from one-time kit sales to recurring access. Service and retention tools help keep its more than 15 million customers engaged.
| FY2025 metric | Value |
|---|---|
| Revenue | $219 million |
| 23andMe+ active subscribers | 500,000+ |
| Customer base | 15 million+ |
Preview the Actual Deliverable
23andMe Reference Sources
This is the actual 23andMe Value Chain Analysis document you'll receive after purchase-no sample, no surprises. The preview you see here is pulled directly from the full report, so the content and format match exactly. Once you complete your purchase, you'll unlock the complete, detailed version ready to use.
Frequently Asked Questions
The genomic database, housing over 15 million records, serves as the central engine for value creation through non-exclusive pharmaceutical partnerships. With approximately 80% of users consenting to research, the company offers a unique scale for drug target validation. This activity maintains a high-margin data license model that balances the high costs of the $700 million operating losses reported before the 2025 reorganization.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.